Telix Doses First Patient in BiPASS™ Trial for Prostate Cancer Imaging
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Clinical Trial Launch: Telix has dosed the first patient in the BiPASS™ trial in the U.S., evaluating the use of Illuccix® and Gozellix® for prostate cancer diagnosis, marking a significant advancement in the company's precision medicine efforts.
- Patient Recruitment Plan: The BiPASS™ trial aims to enroll 250 patients across the U.S. and Australia, seeking to enhance diagnostic accuracy by integrating MRI with PSMA-PET imaging, thereby reducing unnecessary biopsies and improving patient experience.
- Significant Market Potential: With over one million prostate biopsies performed annually in the U.S., of which up to 75% are negative, the success of BiPASS™ could drastically decrease biopsy rates and increase the adoption of PSMA-PET imaging, expanding the potential patient population.
- Industry Leadership: Telix CEO Kevin Richardson emphasized that the trial's initiation not only reflects the company's commitment to patient-centricity and clinical innovation but also aims to lower healthcare costs and risks by reducing invasive biopsies, further solidifying its leadership position in the industry.
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
